References
- 1. A. Misaghi, A. Goldin, M. Awad and A. A. Kulidjian, Osteosarcoma: A comprehensive review, SICOT J. 4 (2018) Article ID 12; https://doi.org/10.1051/sicotj/201702810.1051/sicotj/2017028589044829629690
- 2. S. S. Bielack, S. Hecker-Nolting, C. Blattmann and L. Kager, Advances in the management of osteosarcoma, F1000Res. 5 (2016) Article ID 2767; https://doi.org/10.12688/f1000research.9465.110.12688/f1000research.9465.1513008227990273
- 3. R. A. Durfee, M. Mohammed and H. H. Luu, Review of osteosarcoma and current management, Rheumatol. Ther. 3 (2016) 221–243; https://doi.org/10.1007/s40744-016-0046-y10.1007/s40744-016-0046-y512797027761754
- 4. J. Zhang, P. L. Yang and N. S. Gray, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer 9 (2009) 28–39; https://doi.org/10.1038/nrc255910.1038/nrc255919104514
- 5. T. G. Davies, J. Bentley, C. E. Arris, F. T. Boyle, N. J. Curtin, J. A. Endicott, A. E. Gibson, B. T. Golding, R. J. Griffin, I. R. Hardcastle, P. Jewsbury, L. N. Johnson, V. Mesguiche, D. R. Newell, M. E. M. Noble, J. A. Tucker, L. Wang and H. J. Whitfield, Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor, Nat. Struct. Biol. 9 (2002) 745–749; https://doi.org/10.1038/nsb84210.1038/nsb84212244298
- 6. J. K. Srivastava, G. G. Pillai, H. R. Bhat, A. Verma and U. P. Singh, Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating epidermal growth factor receptor tyrosine kinase, Sci. Rep. 7 (2017) Article ID 5851 (18 pages); https://doi.org/10.1038/s41598-017-05934-510.1038/s41598-017-05934-5551756228724908
- 7. L. Jakobsson, J. Kreuger, K. Holmborn, L. Lundin, I. Eriksson, L. Kjellén and L. Claesson-Welsh, Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis, Dev. Cell 10 (2006) 625–634; https://doi.org/10.1016/j.devcel.2006.03.00910.1016/j.devcel.2006.03.00916678777
- 8. G. Garg, A. Khandelwal and B. S. J. Blagg, Chapter three – Anticancer inhibitors of Hsp90 function: Beyond the usual suspects, Adv. Cancer Res. 129 (2016) 51–88; https://doi.org/10.1016/bs.acr.2015.12.00110.1016/bs.acr.2015.12.001589242226916001
- 9. H. Pópulo, J. M. Lopes and P. Soares, The mTOR signalling pathway in human cancer, Int. J. Mol. Sci. 13(2) (2012) 1886–1918; https://doi.org/10.3390/ijms1302188610.3390/ijms13021886329199922408430
- 10. U. P. Singh, J. K. Srivastava and H. R. Bhat, 161P Discovery of novel 1,3,5-triazine-thiourea based dual PI3K/mTOR inhibitor against non-small cell lung cancer (NSCLC), Ann. Oncol. 27(Suppl. 9) (2016) ix50; https://doi.org/10.1093/annonc/mdw579.01310.1093/annonc/mdw579.013
- 11. N. Hay, The Akt-mTOR tango and its relevance to cancer, Cancer Cell 8(3) (2005) 179–183; https://doi.org/10.1016/j.ccr.2005.08.00810.1016/j.ccr.2005.08.00816169463
- 12. L. Zhang, J. Wu, M. T. Ling, L. Zhao and K.-N. Zhao, The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses, Mol. Cancer 14 (2015) Article ID 87 (13 pages); https://doi.org/10.1186/s12943-015-0361-x10.1186/s12943-015-0361-x449856026022660
- 13. X. Liu, Y. Xu, Q. Zhou, M. Chen, Y. Zhang, H. Liang, J. Zhao, W. Zhong and M. Wang, PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment, Future Oncol.14(7) (2017) 665–674; https://doi.org/10.2217/fon-2017-058810.2217/fon-2017-058829219001
- 14. B. Wang and J. Li, Piceatannol suppresses the proliferation and induced apoptosis of osteosarcoma cells through PI3K/AKT/MTOR pathway, Cancer Manag. Res. 12 (2020) 2631–2640; https://doi.org/10.2147/CMAR.S23817310.2147/CMAR.S238173718270332368141
- 15. Y. Zhang, Q. Weng, J. Han and J. Chen, Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway, Mol. Med. Rep. 21(2) (2020) 675–684; https://doi.org/10.3892/mmr.2019.1088210.3892/mmr.2019.10882694791431974628
- 16. M. W. Bishop and K. A. Janeway, Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma, F1000Res. 5 (2016) Article ID 1590 (6 pages); https://doi.org/10.12688/F1000RESEARCH.8228.110.12688/f1000research.8228.1493781727441088
- 17. J. A. Perry, A. Kiezun, P. Tonzi, E. M. Van Allen, S. L. Carter, S. C. Baca, G. S. Cowley, A. S. Bhatt, E. Rheinbay, C. S. Pedamallu, E. Helman, A. Taylor-Weiner, A. McKenna, D. S. DeLuca, M. S. Lawrence, L. Ambrogio, C. Sougnez, A. Sivachenko, L. D. Walensky, N. Wagle, J. Mora, C. de Torres, C. Lavarino, S. Dos Santos Aguiar, J. A. Yunes, S. R. Brandalise, G. E. Mercado-Celis, J. Melendez-Zajgla, R. Cárdenas-Cardós, L. Velasco-Hidalgo, C. W. M. Roberts, L. A. Garraway, C. Rodriguez-Galindo, S. B. Gabriel, E. S. Lander, T. R. Golub, S. H. Orkin, G. Getz and K. A. Janeway, Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma, Proc. Natl. Acad. Sci. USA 111(51) (2014) E5564–E5573; https://doi.org/10.1073/pnas.141926011110.1073/pnas.1419260111428063025512523
- 18. M. Penel-Page, I. Ray-Coquard, J. Larcade, M. Girodet, L. Bouclier, M. Rogasik, N. Corradini, N. Entz-Werle, L. Brugieres, J. Domont, C. Lervat, S. Piperno-Neumann, H. Pacquement, J.-O. Bay, J.-C. Gentet, A. Thyss, L. Chaigneau, B. Narciso, H. Cornille, J.-Y. Blay and P. Marec-Bérard, Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes), BMC Cancer 15 (2015) Article ID 854 (9 pages); https://doi.org/10.1186/s12885-015-1894-510.1186/s12885-015-1894-5463596826541413
- 19. K. Singh, A. Gangrade, A. Jana, B. B. Mandal and N. Das, Design, synthesis, characterization, and antiproliferative activity of organoplatinum compounds bearing a 1,2,3-triazole ring, ACS Omega 4 (2019) 835–841; https://doi.org/10.1021/acsomega.8b0284910.1021/acsomega.8b02849
- 20. N. S. Goud, V. Pooladanda, G. S. Mahammad, P. Jakkula, S. Gatreddi, I. A. Qureshi, R. Alvala, C. Godugu and M. Alvala, Synthesis and biological evaluation of morpholines linked coumarintriazole hybrids as anticancer agents, Chem. Biol. Drug Des. 94(5) (2019) 1919–1929; https://doi.org/10.1111/cbdd.1357810.1111/cbdd.1357831169963
- 21. G. Silva, M. Marins, A. L. Fachin, S.-H. Lee and S. J. Baek, Anti-cancer activity of trans-chalcone in osteosarcoma: Involvement of Sp1 and p53, Mol. Carcinog. 55(10) (2016) 1438–1448; https://doi.org/10.1002/mc.2238610.1002/mc.2238626294168
- 22. T. Ji, C. Lin, L. S. Krill, R. Eskander, Y. Guo, X. Zi and B. H. Hoang, Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis, Mol. Cancer 12 (2013) Article ID 55 (11 pages); https://doi.org/10.1186/1476-4598-12-5510.1186/1476-4598-12-55368160323764122
- 23. D. Dheer, V. Singh and R. Shankar, Medicinal attributes of 1,2,3-triazoles: Current developments, Bioorg. Chem. 71 (2017) 30–54; https://doi.org/10.1016/j.bioorg.2017.01.01010.1016/j.bioorg.2017.01.01028126288
- 24. K. Bozorov, J. Zhao and H. A. Aisa, 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview, Bioorg. Med. Chem. 27(16) (2019) 3511–3531; https://doi.org/10.1016/j.bmc.2019.07.00510.1016/j.bmc.2019.07.005718547131300317
- 25. Z. Xu, S.-J. Zhao and Y. Liu, 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships, Eur. J. Med. Chem. 183 (2019) Article ID 111700; https://doi.org/10.1016/j.ejmech.2019.11170010.1016/j.ejmech.2019.11170031546197
- 26. S. Vanaparthi, R. Bantu, N. Jain, S. Janardhan and L. Nagarapu, Synthesis and anti-proliferative activity of a novel 1,2,3-triazole tethered chalcone acetamide derivatives, Bioorg. Med. Chem. Lett. 30(16) (2020) Article ID 127304.; https://doi.org/10.1016/j.bmcl.2020.12730410.1016/j.bmcl.2020.12730432631524
- 27. S. Li, J. Wawrzyniak, Y. Queneau and L. Soulère, 2-Substituted aniline as a simple scaffold for LuxR-regulated QS modulation, Molecules 22(12) (2017) Article ID 2090 (10 pages); https://doi.org/10.3390/molecules2212209010.3390/molecules22122090614992229186042
- 28. J. Hu, Y. Zhang, N. Tang, Y. Lu, P. Guo and Z. Huang, Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR, Bioorg. Med. Chem. 32 (2021) Article ID 115997; https://doi.org/10.1016/j.bmc.2021.11599710.1016/j.bmc.2021.11599733440319
- 29. T.-T. Wu, Q.-Q. Guo, Z.-L. Chen, L.-L. Wang, Y. Du, R. Chen, Y.-H. Mao, S.-G. Yang, J. Huang, J.-T. Wang, L. Wang, L. Tang and J. Q. Zhang, Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors, Eur. J. Med. Chem. 204 (2020) Article ID 112637; https://doi.org/10.1016/j.ejmech.2020.11263710.1016/j.ejmech.2020.11263732717477
- 30. C.-H. R. Or, H.-L. Su, W.-C. Lee, S.-Y. Yang, C. Ho and C.-C. Chang, Diphenhydramine induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling and retards B16-F10 melanoma growth in vivo, Oncol. Rep. 36(6) (2016) 3465–3471; https://doi.org/10.3892/or.2016.520110.3892/or.2016.520127779705
- 31. H. F. Ashour, L. A. Abou-zeid, M. A.-A. El-Sayed and K. B. Selim, 1,2,3-Triazole-chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226, Eur. J. Med. Chem. 189 (2020) Article ID 112062; https://doi.org/10.1016/j.ejmech.2020.11206210.1016/j.ejmech.2020.11206231986406
- 32. D.-J. Fu, S.-Y. Zhang, Y.-C. Liu, X.-X. Yue, J.-J. Liu, J. Song, R.-H. Zhao, F. Li, H.-H. Sun, Y.-B. Zhang and H.-M. Liu, Design, synthesis and antiproliferative activity studies of 1,2,3-triazole-chalcones, MedChemComm 7(8) (2016) 1664–1671; https://doi.org/10.1039/c6md00169f10.1039/C6MD00169F
- 33. S.-Y. Zhang, D.-J. Fu, X.-X. Yue, Y.-C. Liu, J. Song, H.-H. Sun, H.-M. Liu and Y.-B. Zhang, Design, synthesis and structure-activity relationships of novel chalcone-1,2,3-triazole-azole derivates as antiproliferative agents, Molecules 21(5) (2016) Article ID 653 (13 pages); https://doi.org/10.3390/molecules2105065310.3390/molecules21050653627451727213317